PulseJournal ClubResearchersJournalsExplore
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
November 4, 2025CureusOpen Access

Late-Onset Immune-Mediated Hepatotoxicity Induced by the Immune Checkpoint Inhibitor Pembrolizumab in Lung Cancer: A Case Report

View Full Paper
Ask AI
Bookmark
Share

Authors

JEJacobo Echeverri-HoyosETEduardo Tuta-QuinteroJFJosé Franco

Discussion

Loading...

Member takes

Overview

Case report highlights liver enzyme elevation in lung cancer patient treated with pembrolizumab, indicating hepatotoxicity risks.

Key Points

  • Hepatotoxicity was observed with persistent elevation of liver enzymes after pembrolizumab treatment, prompting early management.
  • The case emphasizes the diagnostic challenge of immune-mediated adverse events in cancer therapy.
  • Monitoring liver function is crucial during immunotherapy, especially after extensive treatment cycles.
  • This case demonstrates the need for vigilance in recognizing delayed immune-related hepatotoxicity.

Cite This Study

Echeverri-Hoyos et al. (2025) studied this question.

synapsesocial.com/papers/6909452d8f2297dc13532aedhttps://doi.org/10.7759/cureus.95961
View Full Paper
Ask AI
Bookmark
Share